Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-IL13Ra2 nano antibody and application thereof

A nanobody, chimeric antigen receptor technology, applied in the field of biomedicine

Active Publication Date: 2022-04-29
HUADAO SHANGHAI BIOPHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the survival time of first-generation CAR-T cells in the glioma environment is limited to less than 15 days

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-IL13Ra2 nano antibody and application thereof
  • Anti-IL13Ra2 nano antibody and application thereof
  • Anti-IL13Ra2 nano antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] In this example, a phage nanobody library was constructed and panned, and ELISA was used for preliminary screening. The specific steps are as follows:

[0111] (1) Construction of phage nanobody library

[0112] The recombinant protein of IL13Ra2 extracellular segment was used to immunize alpaca, and after the serum titer was detected by ELISA, peripheral blood was drawn; lymphocytes were separated, total RNA was extracted, and then reverse-transcribed into cDNA, and then the VHH gene was amplified by nested PCR; the VHH gene Insert pShort phagemid, electroporation Competent cells, after amplification, separated and purified phages by PEG8000 / NaCI precipitation method to obtain antibody library; adjusted the concentration, subpackaged and frozen in -80°C refrigerator for later use;

[0113] (2) Screening of phage nanobody library

[0114] First, take 293T cells and incubate with the antibody library for negative screening, then take the supernatant and incubate with ...

Embodiment 2

[0116] In this example, the anti-IL13Ra2 nanobody (VHH-mIgG2a Fc nanobody) screened in Example 1 was expressed and purified, and the antibody affinity was measured. In order to further identify the antibodies obtained through screening, it is necessary to express the antibodies through mammalian cells. Therefore, a plasmid vector expressing VHH with a mouse Fc tag was constructed first, which was denoted as C-4pCP.Stuffer-mCg2a-FC. The specific steps are as follows :

[0117] (1) Use PCR to amplify the VHH fragment, the reaction system is as shown in Table 1, and the amplification program is as shown in Table 2 below;

[0118] Table 1

[0119] Table 2

[0120]

[0121]

[0122] (2) The enzyme digestion system is shown in Table 3, the enzyme digestion temperature is 37°C, the time is 6h, and the vector after enzyme digestion is used PCR purification kit for purification, the recovered DNA was dissolved in 45 μL water, and the concentration of DNA was detected;

[012...

Embodiment 3

[0143] In this example, flow cytometry was performed on the anti-IL13Ra2 nanobody of the example.

[0144] 293T (IL13Ra2 negative, IL13Ra2 - ), 293T-Mesothelin cells were mixed with the purified anti-IL13Ra2 nanobody, incubated in ice bath for 30min, then incubated with APC-labeled goat anti-mouse IgG antibody for 30min, and detected by flow cytometry, the results were as follows: figure 2 As shown, it shows that the anti-IL13Ra2 nanobody of the present invention can recognize the IL13Ra2 antigen on the cell surface.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an anti-IL13Ra2 nano antibody and an application of the anti-IL13Ra2 nano antibody. The amino acid sequence of the CDR3 of the nano antibody comprises a sequence as shown in SEQ ID NO. 8, SEQ ID NO. 9 or SEQ ID NO. 10. The anti-IL13Ra2 nano antibody disclosed by the invention can be specifically combined with an IL13Ra2 antigen, is relatively good in affinity, and has obvious killing activity on IL13Ra2 positive tumor cells by taking the anti-IL13Ra2 nano antibody as an antigen binding structural domain to construct a chimeric antigen receptor and a CAR-T (Chimeric Antigen Receptor-T) cell.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an anti-IL13Ra2 nanobody and its application. Background technique [0002] Glioma is the most common primary malignant tumor in the brain. According to the WHO classification, glioma can be divided into grades I to IV according to the degree of malignancy. I and II are low-grade gliomas. They are high-grade gliomas, among which glioblastoma multiforme (GBM) is the most malignant, accounting for more than 80% of malignant gliomas. Despite the rapid development of diagnosis and treatment methods in the past ten years, the prognosis of high-grade gliomas (grade III-IV) is still unsatisfactory due to the characteristics of strong invasion, difficult treatment, poor prognosis and high recurrence rate. only about 14 months [1] , 2-year survival rate <25% [2,3] . Although low-grade gliomas (grades I-II) have a better prognosis, they can still bring neurological s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C12N15/13C12N15/867C12N5/10C07K19/00A61K39/395A61P35/00B82Y5/00A61K39/00
CPCC07K16/2863C07K14/7051C12N15/86A61P35/00B82Y5/00A61K39/0011C07K2317/569C07K2317/565A61K2039/5154A61K2039/5158C07K2319/02C07K2319/03C12N2740/15043Y02A50/30
Inventor 狄升蒙冯冬歌陈鑫李嘉涛范艳秋田琳余学军刘芳
Owner HUADAO SHANGHAI BIOPHARMA CO LTD